-
British Journal of Hospital Medicine Apr 1988Vancomycin is an important antibiotic for the treatment of severe Gram-positive infection, especially in cases with resistant organisms or when the patient is allergic... (Review)
Review
Vancomycin is an important antibiotic for the treatment of severe Gram-positive infection, especially in cases with resistant organisms or when the patient is allergic to penicillin. Because of its mode of action, pharmacokinetics and side effects, close liaison with the medical microbiologist is necessary.
Topics: Bacterial Infections; Humans; Staphylococcus aureus; Staphylococcus epidermidis; Vancomycin
PubMed: 3291996
DOI: No ID Found -
Pharmacotherapy 1995
Comparative Study
Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Utilization; Enterococcus; Humans; Vancomycin
PubMed: 8570445
DOI: 10.1002/j.1875-9114.1995.tb02882.x -
Die Pharmazie Aug 1975
Review
Topics: Administration, Oral; Cell Membrane; Chromatography, Ion Exchange; Dose-Response Relationship, Drug; Drug Stability; Humans; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Peptides; RNA, Bacterial; Staphylococcal Infections; Vancomycin
PubMed: 241090
DOI: No ID Found -
Otolaryngologic Clinics of North America Oct 1993This article details clinical reports and animal studies of ototoxicity associated with vancomycin and its analogues. From these studies, the ototoxicity of these agents... (Review)
Review
This article details clinical reports and animal studies of ototoxicity associated with vancomycin and its analogues. From these studies, the ototoxicity of these agents is still not clear. In the author's opinion, vancomycin must affect the auditory system in a manner that results in augmentation of the usual ototoxicity of aminoglycoside antibiotics. This postulated effect may manifest as a temporary hearing loss in humans. More studies are needed, however, before a definitive conclusion can be made.
Topics: Animals; Cochlea; Hearing Disorders; Humans; Vancomycin
PubMed: 8233491
DOI: No ID Found -
The Journal of Pediatrics Sep 1980
Topics: Biopharmaceutics; Humans; Infusions, Parenteral; Vancomycin
PubMed: 7411320
DOI: 10.1016/s0022-3476(80)80220-4 -
Lancet (London, England)
Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Humans; Streptococcal Infections; Streptococcus; Vancomycin
PubMed: 2891921
DOI: 10.1016/s0140-6736(88)91037-9 -
The Journal of Antimicrobial... Oct 1982
Topics: Bacterial Infections; Vancomycin
PubMed: 7142074
DOI: 10.1093/jac/10.4.257 -
Clinical Infectious Diseases : An... Jan 2006Vancomycin became available for clinical use >50 years ago but was soon discarded in favor of other antibiotics that were deemed to be more efficacious and less toxic....
Vancomycin became available for clinical use >50 years ago but was soon discarded in favor of other antibiotics that were deemed to be more efficacious and less toxic. The advent of pseudomembranous enterocolitis, coupled with the spread of methicillin-resistant Staphylococcus aureus, led to a resurgence in the use of vancomycin. Almost immediately, concerns arose with regard to its therapeutic utility. In addition, resistance to vancomycin developed, first in enterococci and later in staphylococci. Several types of resistance have now been identified, each with a unique effect on infections treated with vancomycin. Recent studies have rekindled interest in the best way to administer the antibiotic. The findings of future studies may result in a return to measuring levels of vancomycin in serum, to assure a successful therapeutic outcome.
Topics: Anti-Bacterial Agents; Enterococcus; Gene Transfer, Horizontal; History, 20th Century; History, 21st Century; Humans; Staphylococcus aureus; Vancomycin; Vancomycin Resistance
PubMed: 16323120
DOI: 10.1086/491709 -
Cancer Journal (Sudbury, Mass.)Although antibiotic is a major contributor to shifts in the intestinal flora that may persist for up to several months after cessation, it is now increasingly recognized... (Review)
Review
Although antibiotic is a major contributor to shifts in the intestinal flora that may persist for up to several months after cessation, it is now increasingly recognized that its prescription may differentially influence clinical outcome of different anticancer treatments. Intense clinical and basic research efforts aim then at gaining sufficient insights about how the cooperative action between the intestinal ecosystem and immune surveillance modulates the efficacy of anticancer treatments. In this review, we summarize multiple levels of knowledge between vancomycin exposure, the gut microbiota, and a meaningful therapeutic response. Furthermore, we discuss the mode of action of antibiotic therapy that is prescribed for prophylaxis of bacteremia and neutropenia and outline the opportunity for judiciously improving the efficacy of anticancer drugs.
Topics: Humans; Vancomycin; Ecosystem; Anti-Bacterial Agents; Gastrointestinal Microbiome
PubMed: 36957980
DOI: 10.1097/PPO.0000000000000652 -
Journal of the American Podiatric... 2004An increased reliance on vancomycin to treat bacterial infections has led to the emergence of vancomycin-resistant organisms. The podiatric physician must select and use... (Review)
Review
An increased reliance on vancomycin to treat bacterial infections has led to the emergence of vancomycin-resistant organisms. The podiatric physician must select and use vancomycin with due caution. This article presents a general review of vancomycin's pharmacology, pharmacokinetics, and dosing recommendations. Literature citations of clinically based evidence regarding the development and use of vancomycin nomograms are also presented. A vancomycin dosing nomogram is introduced as an effective tool for the prescribing podiatric physician. Appropriate use of the information presented may improve patient outcomes and enable the podiatric physician to treat patients with less effort and at a lower cost.
Topics: Anti-Bacterial Agents; Bacterial Infections; Centers for Disease Control and Prevention, U.S.; Humans; Podiatry; United States; Vancomycin
PubMed: 15265999
DOI: 10.7547/0940389